Clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable advanced gastric cancer

In Ji Song, Hyun Ju Kim, Ji Ae Lee, Jun Chul Park, Sung Kwan Shin, SangKil Lee, Yongchan Lee, Hyunsoo Chung

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Bleeding is one of the most serious complications of advanced gastric cancer (AGC) and is associated with a poor prognosis. This study aimed to evaluate the clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable AGC. Materials and Methods: This study included 106 patients with bleeding associated with gastric cancer who had undergone endoscopic hemostasis between January 2010 and December 2013. Clinical characteristics, treatment outcomes, including rates of successful endoscopic hemostasis and rebleeding, risk factors for rebleeding, and overall survival (OS) were investigated. Results: Successful initial hemostasis was achieved in 83% of patients. Rebleeding occurred in 28.3% of patients within 30 days. The median OS after initial hemostasis was lower in patients with rebleeding than in those without rebleeding (2.7 and 3.9 months, respectively, P=0.02). There were no significant differences in disease status and rebleeding rates among patients with partial response or stable disease (n=4), progressive disease (n=64), and first diagnosis of disease (n=38). Univariate and multivariate analyses (P=0.038 and 0.034, respectively) revealed that transfusion of ≥5 units of RBCs was a significant risk factor for rebleeding. Conclusions: Despite favorable success rates of endoscopic hemostasis for bleeding associated with gastric cancer, the 30-day rebleeding rate was 28.3% and the median OS was significantly lower in patients with rebleeding than in those without rebleeding. Massive transfusion (≥5 units of RBCs) was the only significant risk factor for rebleeding. Patients with bleeding associated with AGC who have undergone massive transfusion should be observed closely following endoscopic hemostasis. Further research on approaches to reduce rebleeding rate and prevent death is needed.

Original languageEnglish
Pages (from-to)374-383
Number of pages10
JournalJournal of Gastric Cancer
Volume17
Issue number4
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Endoscopic Hemostasis
Stomach Neoplasms
Hemorrhage
Hemostasis
Survival
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Song, In Ji ; Kim, Hyun Ju ; Lee, Ji Ae ; Park, Jun Chul ; Shin, Sung Kwan ; Lee, SangKil ; Lee, Yongchan ; Chung, Hyunsoo. / Clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable advanced gastric cancer. In: Journal of Gastric Cancer. 2017 ; Vol. 17, No. 4. pp. 374-383.
@article{f76157a276e7450a8f85ec6e78cfa682,
title = "Clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable advanced gastric cancer",
abstract = "Purpose: Bleeding is one of the most serious complications of advanced gastric cancer (AGC) and is associated with a poor prognosis. This study aimed to evaluate the clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable AGC. Materials and Methods: This study included 106 patients with bleeding associated with gastric cancer who had undergone endoscopic hemostasis between January 2010 and December 2013. Clinical characteristics, treatment outcomes, including rates of successful endoscopic hemostasis and rebleeding, risk factors for rebleeding, and overall survival (OS) were investigated. Results: Successful initial hemostasis was achieved in 83{\%} of patients. Rebleeding occurred in 28.3{\%} of patients within 30 days. The median OS after initial hemostasis was lower in patients with rebleeding than in those without rebleeding (2.7 and 3.9 months, respectively, P=0.02). There were no significant differences in disease status and rebleeding rates among patients with partial response or stable disease (n=4), progressive disease (n=64), and first diagnosis of disease (n=38). Univariate and multivariate analyses (P=0.038 and 0.034, respectively) revealed that transfusion of ≥5 units of RBCs was a significant risk factor for rebleeding. Conclusions: Despite favorable success rates of endoscopic hemostasis for bleeding associated with gastric cancer, the 30-day rebleeding rate was 28.3{\%} and the median OS was significantly lower in patients with rebleeding than in those without rebleeding. Massive transfusion (≥5 units of RBCs) was the only significant risk factor for rebleeding. Patients with bleeding associated with AGC who have undergone massive transfusion should be observed closely following endoscopic hemostasis. Further research on approaches to reduce rebleeding rate and prevent death is needed.",
author = "Song, {In Ji} and Kim, {Hyun Ju} and Lee, {Ji Ae} and Park, {Jun Chul} and Shin, {Sung Kwan} and SangKil Lee and Yongchan Lee and Hyunsoo Chung",
year = "2017",
month = "12",
day = "1",
doi = "10.5230/jgc.2017.17.e42",
language = "English",
volume = "17",
pages = "374--383",
journal = "Journal of Gastric Cancer",
issn = "2093-582X",
publisher = "Korean Gastric Cancer Association",
number = "4",

}

Clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable advanced gastric cancer. / Song, In Ji; Kim, Hyun Ju; Lee, Ji Ae; Park, Jun Chul; Shin, Sung Kwan; Lee, SangKil; Lee, Yongchan; Chung, Hyunsoo.

In: Journal of Gastric Cancer, Vol. 17, No. 4, 01.12.2017, p. 374-383.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable advanced gastric cancer

AU - Song, In Ji

AU - Kim, Hyun Ju

AU - Lee, Ji Ae

AU - Park, Jun Chul

AU - Shin, Sung Kwan

AU - Lee, SangKil

AU - Lee, Yongchan

AU - Chung, Hyunsoo

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose: Bleeding is one of the most serious complications of advanced gastric cancer (AGC) and is associated with a poor prognosis. This study aimed to evaluate the clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable AGC. Materials and Methods: This study included 106 patients with bleeding associated with gastric cancer who had undergone endoscopic hemostasis between January 2010 and December 2013. Clinical characteristics, treatment outcomes, including rates of successful endoscopic hemostasis and rebleeding, risk factors for rebleeding, and overall survival (OS) were investigated. Results: Successful initial hemostasis was achieved in 83% of patients. Rebleeding occurred in 28.3% of patients within 30 days. The median OS after initial hemostasis was lower in patients with rebleeding than in those without rebleeding (2.7 and 3.9 months, respectively, P=0.02). There were no significant differences in disease status and rebleeding rates among patients with partial response or stable disease (n=4), progressive disease (n=64), and first diagnosis of disease (n=38). Univariate and multivariate analyses (P=0.038 and 0.034, respectively) revealed that transfusion of ≥5 units of RBCs was a significant risk factor for rebleeding. Conclusions: Despite favorable success rates of endoscopic hemostasis for bleeding associated with gastric cancer, the 30-day rebleeding rate was 28.3% and the median OS was significantly lower in patients with rebleeding than in those without rebleeding. Massive transfusion (≥5 units of RBCs) was the only significant risk factor for rebleeding. Patients with bleeding associated with AGC who have undergone massive transfusion should be observed closely following endoscopic hemostasis. Further research on approaches to reduce rebleeding rate and prevent death is needed.

AB - Purpose: Bleeding is one of the most serious complications of advanced gastric cancer (AGC) and is associated with a poor prognosis. This study aimed to evaluate the clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable AGC. Materials and Methods: This study included 106 patients with bleeding associated with gastric cancer who had undergone endoscopic hemostasis between January 2010 and December 2013. Clinical characteristics, treatment outcomes, including rates of successful endoscopic hemostasis and rebleeding, risk factors for rebleeding, and overall survival (OS) were investigated. Results: Successful initial hemostasis was achieved in 83% of patients. Rebleeding occurred in 28.3% of patients within 30 days. The median OS after initial hemostasis was lower in patients with rebleeding than in those without rebleeding (2.7 and 3.9 months, respectively, P=0.02). There were no significant differences in disease status and rebleeding rates among patients with partial response or stable disease (n=4), progressive disease (n=64), and first diagnosis of disease (n=38). Univariate and multivariate analyses (P=0.038 and 0.034, respectively) revealed that transfusion of ≥5 units of RBCs was a significant risk factor for rebleeding. Conclusions: Despite favorable success rates of endoscopic hemostasis for bleeding associated with gastric cancer, the 30-day rebleeding rate was 28.3% and the median OS was significantly lower in patients with rebleeding than in those without rebleeding. Massive transfusion (≥5 units of RBCs) was the only significant risk factor for rebleeding. Patients with bleeding associated with AGC who have undergone massive transfusion should be observed closely following endoscopic hemostasis. Further research on approaches to reduce rebleeding rate and prevent death is needed.

UR - http://www.scopus.com/inward/record.url?scp=85040786066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040786066&partnerID=8YFLogxK

U2 - 10.5230/jgc.2017.17.e42

DO - 10.5230/jgc.2017.17.e42

M3 - Article

AN - SCOPUS:85040786066

VL - 17

SP - 374

EP - 383

JO - Journal of Gastric Cancer

JF - Journal of Gastric Cancer

SN - 2093-582X

IS - 4

ER -